The Yuan requests your support! Our content will now be available free of charge for all registered subscribers, consistent with our mission to make AI a human commons accessible to all. We are therefore requesting donations from our readers so we may continue bringing you insightful reportage of this awesome technology that is sweeping the world. Donate now
DL boosts India’s drug development - part 1
By Priya Dialani  |  Feb 09, 2023
DL boosts India’s drug development - part 1
Image courtesy of and under license from
India has long been a hub of pharmaceutical development and production and many Indian startups in this domain have lately turned to technology - especially AI and ML - to cut the time, cost, and effort needed to develop new drugs and gain approval for their use, which formerly took many years.

MUMBAI - India's medicinal development dates back to the 2nd millennium BCE. Its ancient yet very effective medication - known as the Ayurvedic system - is still widely used for the prevention and treatment of chronic diseases. The significance of Ayurveda remains unshaken among many Indians today, despite the recent strides that have been made in modern drug development in India.1 Lately, many Indian pharma companies have been using traditional medicine components to lessen the adverse effects of various medicines.

Consumers are now more mindful of their health than they used to be - including the type of medicines that least affect the body - especially after the outbreak of the Covid-19 pandemic. In addition, the Indian pharma landscape is witnessing an increasing number of drug development startups that focus on using technology - primarily artificial intelligence (AI) and machine learning  - to develop innovative medicines.2

Problems in drug development

Companies like AIRA Matrix are now leveraging the power of AI and innovating drugs that advance healthcare.3 Fundamentally, drug development is an expensive and time-consuming process, and it can take over 10 years of hard work to produce just one effective and acceptable medicine. However, AI can be a key player here, as its predictive capabilities are able to reduce false possibilities and eliminate dependence on predetermined targets - traditional systems typically must rely on a known target. AI’s cutting-edge algorithms can also advance the speed, accuracy, and precision of drug development.4

Realizing the significance of AI in drug development, Chaith Kondragunta, chief executive of AIRA Matrix, believes in the opportunities presented by using AI in the preclinical drug development phase. Kondragunta has also stated

The content herein is subject to copyright by The Yuan. All rights reserved. The content of the services is owned or licensed to The Yuan. Such content from The Yuan may be shared and reprinted but must clearly identify The Yuan as its original source. Content from a third-party copyright holder identified in the copyright notice contained in such third party’s content appearing in The Yuan must likewise be clearly labeled as such.
Continue reading
Sign up now to read this story for free.
- or -
Continue with Linkedin Continue with Google
Share your thoughts.
The Yuan wants to hear your voice. We welcome your on-topic commentary, critique, and expertise. All comments are moderated for civility.